Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Azacitidine 66venetoclax 21Decitabine 16Cytarabine 12decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 7fludarabine 6pevonedistat 5mocetinostat 5ON 01910 5Busulfan 5treosulfan 4sabatolimab 4ruxolitinib 4cedazuridine 4cc-486 4Mycophenolic Acid 4Lenalidomide 4Injections 4plerixafor 3luspatercept 3imetelstat 3glasdegib 3fludarabine phosphate 3Whole-Body Irradiation 3Methotrexate 3GRN163L peptide 3Clofarabine 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic Syndromes × sapacitabine × Clear all
NCT00380653 2021-12-13

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
47 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Cyclacel Pharmaceuticals, Inc.

Phase 1/2 Unknown
65 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡